◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST MEDIUM

Solriamfetol

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST MEDIUM

Re-eval lift from prior SKIP — 2024-2025 data is genuinely interesting (SHARP cognitive trial in OSA, FOCUS Phase 3 ADHD success, NEJM Evidence shift work data), and 71% real-world preference over modafinil/armodafinil among switchers is a meaningful signal. But Dylan's PRIMARY-PICK is modafinil at $0.50-1.50/pill gray-market vs solriamfetol at $1,100-1,200/mo brand-only with no generic until ≥2031, and the BP-elevation profile is real (more pronounced than modafinil). Verdict would shift to STRONG-CANDIDATE if Dylan develops modafinil intolerance (rash, headache, anxiety) AND can secure US Rx via sleep specialist; would shift to OPTIONAL-ADD if FOCUS-style ADHD data replicates or off-label prescribing pathway opens.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    Modafinil is PRIMARY-PICK at $0.50-1.50/pill gray-market with 25+ years safety data; solriamfetol's $1,100+/mo cost + Rx friction don't justify a switch unless modafinil fails. Trigger to lift: modafinil-induced rash (SJS watch first 8 weeks), persistent headache, or unmanageable anxiety on modafinil. Cleaner subjective profile per anecdote, but BP elevation risk is more pronounced — not a free win.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same modafinil-first logic, but executive demographics often have insurance that cuts the cost barrier. SHARP cognitive enhancement signal in this age range (OSA peaks 40+) is genuinely interesting.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    with caution. OSA prevalence + cognitive enhancement signal + EDS overlap make this a reasonable consideration, but BP/CV risk profile in older adults skews the calculus toward modafinil unless clinically necessary.

  • Anxiety-prone
    SKIP

    NE component drives anxiety in 5-10% of users. Modafinil or pitolisant safer choice. (Note preclinical mouse data argues opposite, but human signal points anxiogenic.)

  • High athletic load, tested status
    SKIP

    for tested athletes. Solriamfetol is NOT explicitly on WADA list as of 2026 but as a sympathomimetic stimulant analog, it carries class-effect risk. Dylan untested, so this doesn't bind him.

  • Sleep-disordered (narcolepsy / OSA EDS)
    STRONG-CANDIDATE

    clinical. A-tier evidence for indicated populations; SHARP added cognitive signal in OSA. Reasonable first or second-line FDA-approved option.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    Sympathomimetic load + BP elevation work against recovery physiology. Pick something parasympathetic-friendly.

  • Strength/anabolic-focused
    SKIP

    Appetite suppression and sympathetic load conflict with caloric surplus needs.

  • Shift workers
    STRONG-CANDIDATE

    2026 NEJM Evidence early-morning SWD trial is the cleanest treatment data for this population to date. Modafinil still primary (cheaper, longer half-life), solriamfetol close second especially if shorter half-life is desired (less spillover into sleep recovery).

▸ Subjective experience (deep)

Per user reports + clinical trial AE patterns:

  • Onset: ~30-60 min, peak around 2 hr.
  • Peak experience: Cleaner wakefulness than amphetamines (no jitter, no euphoria, no tunnel vision); more energizing than modafinil for most users — "brighter, more motivated" is the common descriptor. Less of modafinil's "wired but quiet" character — more of a "drive" feel.
  • Duration: Solid 6-9 hr functional window. Half-life ~7 hr means cleared by bedtime if dosed before 9 AM.
  • Taper: Gentler than amphetamine crash; shorter than modafinil's tail. Some users report mild fatigue rebound by 6-8 PM as plasma levels decline.
  • Anxiety profile: Mixed. Some users find it less anxiogenic than modafinil (preclinical mouse data backs this); others find it MORE anxiogenic, especially at 300 mg. The norepinephrine component is responsible for both the "drive" and the anxiety in users who experience it.
  • Cognitive feel: SHARP study suggests independent cognitive lift. Users describe "executive function comes back online" — better task-switching, better verbal fluency. Less of modafinil's hyperfocus; more of a balanced PFC engagement.
  • Cardiovascular feel: Most users notice mild HR elevation (5-10 bpm) and resting BP elevation (3-5 mmHg) within first 2 weeks. Usually subsides with continued use; ~5-10% of users have it persist and have to discontinue.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal-to-none reported in 52-week open-label data (Malhotra 2020). Similar profile to modafinil — DAT inhibition without DA-flooding doesn't drive tolerance the way amphetamines do.
  • Recommended cycle: Daily-safe per FDA label and clinical use. Some users self-cycle 5-6 days/week with weekend off for sleep architecture preservation, similar to modafinil protocols.
  • Reset protocol: Not typically needed. If anxiety/BP creep emerges, 1-2 week washout usually restores baseline.
  • Withdrawal: No physical dependence in animal or clinical studies. Discontinuation may produce return of EDS in indicated populations but no rebound symptoms.
▸ Stacking deep dive

Synergistic with

  • L-theanine 200 mg AM: Tempers norepinephrine-driven anxiety/BP without blunting wake-promotion. Most-recommended adjunct.
  • Magnesium glycinate 200-400 mg AM: BP buffer + anxiety reduction.
  • Citicoline 250-500 mg AM: PFC acetylcholine support pairs well with the DA/NE drive — anecdotal cognitive synergy.

Avoid stacking with

  • MAOIs (any): 14-day washout BOTH directions REQUIRED. Hypertensive crisis + serotonin syndrome risk. Includes selegiline at higher doses (>10 mg/day, where MAO-A selectivity is lost) — at Dylan's planned 1-2.5 mg AM selegiline, MAO-B selectivity is preserved but caution still warranted; do not co-administer without prescriber guidance.
  • Stimulants (amphetamine, methylphenidate): Additive sympathomimetic load → BP + HR + anxiety stacking. Avoid concomitant unless explicitly directed.
  • Modafinil / armodafinil: Redundant mechanism; don't stack — switch.
  • Bupropion: Both NDRI → additive seizure-threshold lowering + sympathomimetic stack. Avoid.
  • SNRIs (venlafaxine, duloxetine): NE-NE additive load, BP risk. Use cautiously.
  • Caffeine high-dose (>300 mg/day): Additive HR + BP + anxiety. Keep total daily caffeine ≤200 mg if on solriamfetol.

Neutral / safe co-administration

  • DHA / fish oil
  • Magnesium (any form)
  • NAC, citicoline, phosphatidylserine
  • Creatine
  • Beta-alanine
  • Vitamin D3, K2
  • Ashwagandha (may even buffer the BP component)
  • Rhodiola (low dose; high doses can stack on the stimulant feel)
  • Apigenin (no known interaction)
  • Russian peptides (Bromantane, Semax, Selank, Adamax) — no direct interaction; bromantane's anxiolytic profile may complement
▸ Drug interactions deep dive
  • CYP enzymes: Solriamfetol is NOT metabolized by CYP — ~95% renal excretion as unchanged drug. Minimal CYP-mediated drug interactions — major advantage over modafinil (which is a strong CYP3A4 inducer).
  • Hormonal contraceptives: No significant interaction (unlike modafinil, which can reduce contraceptive efficacy via CYP3A4 induction). This is a real practical advantage for female patients.
  • MAOIs: 14-day washout required (see Stacking).
  • Dopaminergic / sympathomimetic stack: Caution.
  • Renally cleared drugs competing for active tubular secretion: Theoretical interaction (probenecid, cimetidine) — limited clinical relevance reported.
  • Alcohol: No specific PK interaction; both are CNS-active so additive effects on judgment / impulse possible. Dylan is zero-alcohol baseline, irrelevant.
▸ Pharmacogenomics

Minimal clinically actionable pharmacogenomics — the main reason: solriamfetol bypasses CYP metabolism (~95% renal), so the major CYP polymorphism story (2D6, 2C19, 3A4) doesn't drive interpatient variability. This is in stark contrast to modafinil (CYP3A4 inducer), bupropion (CYP2B6 prodrug — phenotype matters enormously), or amphetamines (CYP2D6 partial).

What matters instead:

  • Renal function (eGFR): The single biggest variability driver. CKD patients need dose adjustment.
  • DAT / NET / TAAR1 polymorphisms: Theoretically relevant but no actionable clinical data yet.
  • COMT Val158Met: Same general principle as for modafinil/amphetamines — Met/Met (slow COMT, higher baseline PFC DA) may need lower dose or feel anxious; Val/Val may need higher dose or feel less effect. No solriamfetol-specific COMT trial published as of 2025-2026.

For Dylan: his 23andMe results land June 2026. Renal function will be on the bloodwork panel. Once both are in, COMT genotype could inform whether solriamfetol would be a worse or better fit than modafinil — but evidence here is thin.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (insurance) Sleep specialist + commercial pharmacy $9-50/mo with savings card High Sunosi savings card: $9 for 90-day supply if eligible; prior auth typically required. Manufacturer: Axsome.
US Rx (cash) Retail pharmacy (CVS, Walgreens, etc.) $1,100-1,230/mo retail High Brand-only. GoodRx cuts to ~$960/mo.
US Rx (mail-order with savings card) Axsome Direct / specialty pharmacy $9-150/mo High Best path if insured.
Gray-market / Indian pharmacy Limited availability ~$200-400/mo (variable) Low-Medium Solriamfetol has a much narrower gray-market footprint than modafinil/armodafinil because it's newer, fewer Indian generics available, and patent enforcement has been more active. NOT a reliable substitute for the Indian modafinil pipeline Dylan already uses.
Generic NOT AVAILABLE — — Compound patent (USPN 8,642,777) expires ~2031 absent successful challenge. Realistically: no generic before 2030.

For Dylan specifically: No reliable cheap path exists. If the medical case justifies it (modafinil-intolerant), the route is: (1) sleep specialist consultation → narcolepsy or OSA EDS workup → Sunosi Rx with savings card. Otherwise, this is a $1,000+/mo brand-only drug.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • BP (3 measures over 1 week, average; supine + standing)
  • Resting HR
  • HRV (Oura/ring overnight) — 7-day baseline
  • Sleep architecture (Oura — onset latency, deep, REM)
  • eGFR + creatinine (renal function — single biggest PK driver)
  • Anxiety baseline (GAD-7 or VAS 0-10)
  • Headache frequency baseline (last 30 days)

During use

  • BP daily for first 2 weeks (cuff, AM pre-dose AND 2 hr post-dose)
  • BP weekly thereafter
  • HR + HRV nightly (Oura)
  • Sleep onset latency (Oura) — watch for >30 min increase
  • Anxiety VAS 1-2× weekly
  • Headache + nausea frequency log

Post-cycle (if discontinued)

  • BP — should normalize within 1 week
  • Renal function recheck if continued >12 months
▸ Controversies / open debates Live debate
  1. Cognitive enhancement vs wakefulness: SHARP study claims true cognitive enhancement independent of sleepiness reduction. Critics: small n=59, crossover design with carryover risk, RBANS effect size 0.36 is modest. Supporters: regression analysis was clean and replicates a signal modafinil never demonstrated independently in OSA.
  2. Modafinil vs solriamfetol superiority: 71% switch-preference data (SLEEP 2025 abstract 0864) is suggestive but selection-biased — these were patients dissatisfied with modafinil. Treatment-naive head-to-head RCT does not exist as of 2026. The mouse anxiety data (Black 2023) argues less anxiogenic than modafinil in animals; human signal is mixed-to-opposite. Real answer: probably population-dependent, with a NE-tolerant subgroup preferring solriamfetol and an NE-sensitive subgroup preferring modafinil.
  3. BP elevation magnitude: Trials showed average +0.5 to +2.5 mmHg SBP — small in mean, but distribution matters. Pharmacovigilance 2025 (PMC12453233) flagged real BP signals in OSA cohort. Dose 300 mg has noticeably worse BP profile than 150 mg, supporting 150 mg as the practical max.
  4. TAAR1 mechanism — real or noise? 2024 preclinical data placed TAAR1 agonism at clinically relevant concentrations, but no in vivo validation in humans yet. Plausible but not proven contributor.
  5. Long-term cardiovascular safety: No 5+ year MACE data. Pharmacovigilance signal is real but small. Open question whether sustained mild BP elevation in chronic use translates to MACE excess.
  6. Cost vs benefit: Brand-only $1,100+/mo until ≥2031 generic. Even with savings cards, real-world access is limited. ITC suggests slight efficacy edge over modafinil but the magnitude doesn't obviously justify 100-1000× cost differential for healthy off-label users.
  7. ADHD off-label / future indication: FOCUS Phase 3 success March 2025 sets up potential FDA expansion. If approved for ADHD, would reshape the cognitive-enhancement landscape — but still brand-only. Dylan probably doesn't need ADHD-grade intervention; modafinil + bromantane should saturate the use case.
  8. Re-eval from prior SKIP: Encyclopedia (2026-05-05) prior verdict was effectively SKIP for Dylan because modafinil dominates on cost + safety + Rx access. The 2024-2025 cognitive enhancement (SHARP) + ADHD (FOCUS) + shift work (NEJM Evidence) data is genuinely new and meaningful — but doesn't change the cost arithmetic. Lift from SKIP to WATCH-LIST is the honest re-eval — it's now a serious second-line option, not a curiosity.
▸ Verdict change log
  • 2026-05-05 (encyclopedia) — Implicit verdict: SKIP / "Second-line backup" — modafinil dominates on cost + access; solriamfetol shorter half-life is a theoretical upside but mixed user satisfaction data.
  • 2026-05-05 (this file) — Lifted to WATCH-LIST. Rationale: 2024-2025 evidence (SHARP cognitive trial, FOCUS Phase 3 ADHD success, NEJM Evidence shift work, 71% real-world preference data) is genuinely meaningful — solriamfetol is no longer just "alternative wakefulness drug" but a candidate with independent cognitive enhancement signal, which is rare. However, $1,100+/mo brand-only cost + no generic until ≥2031 + harder BP profile + thin gray-market sourcing keep it below modafinil for Dylan's primary protocol. Trigger to STRONG-CANDIDATE: modafinil intolerance (rash/headache/anxiety) AND US Rx pathway secured. Trigger to OPTIONAL-ADD: insurance coverage + sleep specialist Rx + favorable BP at 75 mg trial.
▸ Open questions / gaps Open
  1. Treatment-naive head-to-head RCT vs modafinil — does not exist. All comparison data is indirect or selection-biased.
  2. Long-term (5+ yr) MACE data — not yet available.
  3. Cognitive enhancement in healthy non-EDS adults — no published data. SHARP was OSA-specific. Whether solriamfetol enhances cognition in baseline-rested healthy adults (modafinil's well-studied off-label use case) is unknown.
  4. TAAR1 contribution in vivo (human) — preclinical only.
  5. Pregnancy + lactation safety — limited; not approved in pregnancy.
  6. Pediatric / adolescent data — none. Not approved <18.
  7. Tolerance beyond 12 months — open-label extensions out to 1 year, but not 2-5 yr durability data at scale.
  8. Generic launch timing — patent landscape suggests no generic before 2030-2031, but Axsome has been aggressive with patent litigation. A successful Paragraph IV challenge could shift this materially.
  9. Off-label cognitive enhancement community uptake — currently negligible due to cost. If insurance shifts or generic launches early, this could explode.
▸ Sources (full, with our context)
Back to compact view